US · Healthcare · Biotechnology
EPS came in at -0.15 against a street estimate of -0.13 — a miss of 15.4%.
Analysts rate ProKidney Corp. a buy (4 buy, 3 hold, 0 sell out of 7) with an average price target of $6.25.
| Fund | Stake |
|---|---|
| Suvretta Capital Management, LLC | 5.91% |
| Morgan Stanley - Brokerage Accounts | 4.29% |
| Bleichroeder LP | 0.96% |
| Hennion & Walsh Asset Management Inc | 0.88% |
| Artia Global Partners LP | 0.86% |
| BlackRock Inc | 0.66% |
| Renaissance Technologies Corp | 0.60% |
| Geode Capital Management, LLC | 0.59% |
| Document | Date |
|---|---|
| Quarterly report · Q2 2026 PROKINNEY CORP. 10-Q SUMMARY FOR RETAIL INVESTORS HEADLINE NUMBERS • Cash Position: $74.9 million in cash and $106.7 million in marketable securitie | 2026-08-10 |
| Results announced · Q3 2026 PROKIDNEY CORP. Q2 2026 FINANCIAL SUMMARY HEADLINE NUMBERS • Cash and marketable securities: $181.6 million as of June 30, 2026 (down from $224.9 mi | 2026-08-10 |
| Shareholder vote results · Q2 2026 PROKIDNEY CORP. - 8-K SUMMARY HEADLINE NUMBERS • Annual Meeting of Stockholders held May 28, 2026 • Total votes cast for board director elections: a | 2026-05-29 |
| Quarterly report · Q1 2026 PROKIDNEY CORP. — 10-Q SUMMARY (Q1 2026) --- HEADLINE NUMBERS • Cash position: $101.9 million in cash and cash equivalents as of March 31, 2026 (do | 2026-05-15 |
| Results announced · Q2 2026 PROKIDNEY CORP. – Q1 2026 FINANCIAL SUMMARY HEADLINE NUMBERS • Cash and marketable securities: $224.9 million as of March 31, 2026 (down from $270.0 | 2026-05-15 |
| Proxy statement · Q2 2026 PROKIDNEY CORP. PROXY STATEMENT SUMMARY CEO COMPENSATION • Bruce Culleton, M.D. (CEO) compensation figures not disclosed in provided document sectio | 2026-04-17 |
| Annual report FY2025 PROKIDNEY CORP. – 10-K SUMMARY FOR RETAIL INVESTORS HEADLINE NUMBERS • Public float (market cap of non-affiliate shares): $58.9 million as of June 3 | 2026-03-18 |
| Results announced · Q1 2026 PROKIDNEY CORP. FINANCIAL RESULTS & BUSINESS HIGHLIGHTS SUMMARY HEADLINE NUMBERS • Cash Position: $270.0 million in cash, cash equivalents and marke | 2026-03-18 |
Readable in the app.
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for ProKidney Corp. — free to start.
Google PlayApp StoreData updated 2026-09-18.